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Although osteoporosis and its related fractures are common in patients with COPD, patients at high risk of fracture
are poorly identified, and consequently, undertreated. Since there are no fracture prevention guidelines available
that focus on COPD patients, we developed a clinical approach to improve the identification and treatment of
COPD patients at high risk of fracture. We organised a round-table discussion with 8 clinical experts in the field of
COPD and fracture prevention in the Netherlands in December 2013. The clinical experts presented a review of the
literature on COPD, osteoporosis and fracture prevention. Based on the Dutch fracture prevention guideline, they
developed a 5-step clinical approach for fracture prevention in COPD. Thereby, they took into account both classical
risk factors for fracture (low body mass index, older age, personal and family history of fracture, immobility, smoking,
alcohol intake, use of glucocorticoids and increased fall risk) and COPD-specific risk factors for fracture (severe airflow
obstruction, pulmonary exacerbations and oxygen therapy). Severe COPD (defined as postbronchodilator FEV1 < 50%
predicted) was added as COPD-specific risk factor to the list of classical risk factors for fracture. The 5-step clinical
approach starts with case finding using clinical risk factors, followed by risk evaluation (dual energy X-ray
absorptiometry and imaging of the spine), differential diagnosis, treatment and follow-up. This systematic clinical
approach, which is evidence-based and easy-to-use in daily practice by pulmonologists, should contribute to optimise
fracture prevention in COPD patients at high risk of fracture.
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COPD is a major cause of morbidity and mortality
worldwide and results in a high and steadily increasing
economic and social burden. The prevalence of COPD is
approximately 9 to 10% in adults aged 40 or older [1].
COPD was the fifth leading cause of death in the world
in 2002, and is projected to be the third leading cause of
death by 2030 [2].
COPD is being considered as a complex and heteroge-
neous disease with clinically significant comorbidities
[3,4]. These comorbidities are more often seen in both
COPD patients and smokers than in non-smokers [3,5].
The majority of COPD patients has 4 or more co-
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unless otherwise stated.diseases, gastro-oesophageal reflux, depression, anxiety and
osteoporosis are most frequently found [7].
A meta-analysis stated that the overall prevalence of
osteoporosis in COPD is 35% [8]. A cross-sectional
study with 27 patients with moderate COPD, 45 patients
with severe COPD and 13 patients with very severe
COPD (92% men, mean age 75 years) demonstrated that
35% of patients had 1 or more radiographic vertebral
fractures [9]. In this study, patients with postbronchodi-
lator FEV1 < 30% predicted were at higher risk of verte-
bral fracture compared with patients with FEV1 ≥ 50%
predicted (p = 0.02). A cross-sectional study with 3030
COPD patients (58% men, mean age 70 years) showed
that 35% of patients with mild COPD, 38.5% of patients
with moderate COPD, 45.7% of patients with severe
COPD and 59.2% of patients with very severe COPD
had 1 or more vertebral fractures [10]. In 87360 men
with COPD (mean age 67 years, no data on COPD se-
verity reported), the hip fracture rate was 4.0 per 10005 This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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person years during a follow-up of 2.7 years [11]. Fur-
thermore, a cross-sectional study with 71 patients with
mild COPD, 100 patients with moderate COPD, 57 pa-
tients with severe COPD and 27 patients with very
severe COPD (62% men, mean age 68 years) showed
that 51% of patients had osteoporosis, defined as a
T-score ≤ −2.5 or a prevalent vertebral fracture [12].
However, the majority (80%) of patients with osteoporosis
was not treated with anti-osteoporosis medication.
Osteoporosis-related fractures may contribute to
increased morbidity and mortality in COPD. Indeed,
vertebral fractures may further reduce the already com-
promised pulmonary function in COPD [13] and hip
fractures may increase mortality due to a higher oper-
ation risk related with COPD [14]. Since COPD patients
with increased fracture risk are poorly identified, and
consequently, undertreated [12], we propose a 5-step
clinical approach [15] to improve identification of COPD
patients at high risk of fracture by taking into ac-




A round-table discussion was organised with 8 clinical
experts in the field of COPD and fracture prevention
(3 pneumologists, 2 rheumatologists, 1 endocrinolo-
gist and 2 clinical researchers) in the Netherlands in
December 2013. Three of them were involved in the last
revision of the Dutch guideline on fracture prevention in
2011. The Dutch guideline was developed by, and devel-
oped for, all groups involved in fracture prevention
(general practitioners, specialists, nurses and patients’ or-
ganisations). Every member of the working group studied
the literature over the past 10 years on the following
topics: the prevalence of osteoporosis and fractures
in COPD, classical and COPD-specific risk factors
for osteoporosis and fracture, the role of oral and in-
haled glucocorticoids on osteoporosis and fracture,
and fracture prevention. The literature research was
discussed during the round-table discussion with par-
ticular focus on the following topics: COPD-specific
risk factors for osteoporosis and fracture, and intro-
duction of a systematic clinical approach for fracture
prevention in COPD.
Risk factors for fracture in COPD
Classical risk factors for osteoporosis and fracture in-
clude low body mass index (BMI), older age, previous
fracture before the age of 50, parent with a fracture, im-
mobility, current smoking, alcohol intake (3 or more
units a day), use of glucocorticoids, secondary osteopor-
osis and increased fall risk [16]. In addition to theseclassical risk factors, there are several COPD-specific
risk factors for osteoporosis and fracture, including se-
vere airflow obstruction [17,18], emphysema, exacerba-
tions and oxygen therapy [8-11,19]. In accordance to the
flowchart of Lehouk and colleagues [20], severe COPD
(defined as postbronchodilator FEV1 < 50% predicted)
was included as a supplementary risk factor in our
clinical approach for fracture prevention. Other COPD-
specific risk factors were not included because of lack of
thresholds for inclusion as a risk factor.
Oral glucocorticoids
Oral glucocorticoids are dose-dependently related with a
decrease in bone mineral density (BMD) and increase
in fracture risk [21,22]. In patients who use oral gluco-
corticoids, the relative risk of a vertebral fracture is 2.6
(2.3–2.9), a non-vertebral fracture 1.3 (1.3-1.4), a hip
fracture 1.6 (1.5-1.8) and a wrist fracture 1.1 (1.0-1.2)
[22]. Fracture risk increases immediately after starting
glucocorticoid therapy and decreases quickly after stop-
ping glucocorticoid therapy [22].
Inhaled glucocorticoids
Inhaled glucocorticoids were developed to reduce sys-
temic side-effects. Since part (10 to 40%) of the inhaled
glucocorticoids that reaches the lungs will also come
into the systemic circulation via the bronchial circula-
tion, inhaled glucocorticoids may still cause some sys-
temic side-effects [23,24]. Pouw and colleagues [25]
demonstrated that the use of inhaled beclometason was
related with decreased serum osteocalcin concentrations
that may contribute to reduced bone formation.
Data on the systemic clinical effects of inhaled glu-
cocorticoids have been conflicting. A Cochrane review
of the literature showed that inhaled glucocorticoids
had no effect on BMD or fracture risk during a
follow-up of 3 years [26]. However, a meta-analysis of
16 randomised controlled trials and 7 observational
studies showed that inhaled glucocorticoids were re-
lated with a significant increased risk of fracture (OR 1.27
(1.01 – 1.58)) during a mean trial duration of 90 weeks
[27]. An increase of 500 mcg beclometason equivalents
per day was related with a 9% increased risk of fracture
(1.1 (1.06-1.12)) [27].
Systemic inflammation
Systemic inflammation might be one of the key compo-
nents in the development of COPD-related comorbidities
[28]. Inflammatory markers, such as C-reactive protein, fi-
brinogen, tumor necrosis factor-alpha, interleukin-6 and
interleukin-8, have been shown to be increased in the per-
ipheral blood in COPD patients, compared with smokers
who have not developed the disease [29,30]. Systemic in-
flammation might be the result of a systemic “spill-over”
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[31], or might represent a systemic component of the dis-
ease that develops in parallel with, or prior to, pulmonary
inflammation [32]. Tobacco smoking, tissue hypoxia, in-
fections and exacerbations might also contribute to sys-
temic inflammation.
Increased systemic inflammation is related with the
presence of several COPD-related comorbidities, includ-
ing osteoporosis [32]. Systemic inflammation might
cause abnormalities in the balance and rate of bone re-
modeling via disturbances in the RANK/RANKL/OPG
pathway [33-35]. These abnormalities in bone remodel-
ling might consequently result in bone fragility and in-
creased fracture risk. Clinical studies confirming a causal
relationship between systemic inflammation and bone
alterations in COPD patients have not been published
yet.
Since glucocorticoids are prescribed to decrease lung
inflammation, they may be expected to inhibit systemic in-
flammation and hence exhibit some positive effects on
bone. In patients with rheumatoid arthritis, therapy with
methotrexate and prednisone 10 mg per day led to de-
creased disease activity but did not reduce BMD compared
with methotrexate monotherapy [36]. In 176 patients with
bronchitis, therapy with low dose inhaled glucocorticoids
was related with a reduced loss of BMD compared with ther-
apy without inhaled glucocorticoids (0.002 g/cm2/year
versus 0.006 g/cm2/year, p = 0.02) [37].
Repair processes
A pathway that has been related with both COPD and
osteoporosis is the Wnt/β-catenin signaling pathway. On
the one hand, it plays a role in bone remodeling and re-
pair of micro fractures, while on the other hand, it is in-
volved in lung epithelial injury and repair processes [38].
Therefore, impairment of Wnt/β-catenin signaling might
result in both COPD and osteoporosis.Figure 1 A multistep evaluation and treatment plan for fracture prev
lumbar spine; VFA = vertebral fracture assessment with DXA.A systematic approach for fracture prevention in COPD
Since COPD patients with increased fracture risk are
poorly identified and undertreated, we propose a sys-
tematic evaluation and treatment plan for fracture
prevention in COPD. This 5-step clinical approach
starts with clinical case finding, followed by risk
evaluation, differential diagnosis, treatment and follow-
up (Figure 1). In each step, recommendations are
graded as “strongly recommended”, “recommended”
and “considered useful” based on the strength of evi-
dence (Figures 1,2,3 and 4) [15,16,20].
Step 1: Case finding
In case doctors or patients have questions about fracture
risk, COPD patients who are 50 years or older are rec-
ommended to be assessed for fracture risk using the
COPD-adapted risk score (Table 1). This COPD-adapted
risk score is based on the revised Dutch guideline on
fracture prevention [16] and the flowchart of Lehouck
and colleagues [20].
COPD patients who are 50 years or older and fulfil
one or more of the criteria below are advised further
fracture risk evaluation as described in step 2:
1. A prevalent non-traumatic vertebral fracture,
2. A recent non-vertebral fracture (during the last
2 years),
3. Current use of glucocorticoids (≥7.5 mg prednisone
equivalents per day during at least 3 months),
4. A COPD-adapted fracture risk score ≥4 (Table 1).
Step 2: Risk evaluation
The above mentioned COPD patients are advised further
fracture risk evaluation, which includes dual energy
X-ray absorptiometry (DXA) of the hip and spine,
imaging of the spine and evaluation of clinical risk
factors (Figure 2).ention in COPD. DXA = dual energy X-ray absorptiometry of hip and
Figure 2 Evaluation of fracture risk in COPD patients. DXA = dual energy X-ray absorptiometry of hip and lumbar spine, FRAX = fracture risk
assessment tool, VFA = vertebral fracture assessment with DXA, X-spine = X-ray of the spine. This figure is based on the Dutch guideline on
osteoporosis and fracture prevention [16].
Figure 3 Flowchart for follow-up. This figure is based on the Dutch guideline on osteoporosis and fracture prevention [16].
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Figure 4 Re-evaluation after 5 years of treatment with bisphosphonate or 2 years of treatment with teriparatide. This figure is based on
the Dutch guideline on osteoporosis and fracture prevention [16].
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For diagnostic purposes, osteoporosis is defined as a
BMD 2.5 standard deviations or more below the refer-
ence mean (T-score ≤ −2.5) and osteopenia as a BMD
2.5 to 1.0 standard deviations below the reference mean
(T-score between −1.0 and −2.5). Patients with osteopor-
osis of the hip or spine and patients with osteopenia
who have additional risk factors, such as a newlyTable 1 COPD-adapted risk score
Risk factor
Weight <60 kg or BMI <20 kg/m2 1
Age >60 years 1
Age >70 years (in this case do not count risk score ‘age >60 years’) 2
Previous fracture after the age of 50 (more than 2 years ago) 1
Parent with hip fracture 1
Immobility 1
Rheumatoid arthritis 1
More than 1 fall in the last year 1
Diseases or medications associated with increased fracture risk* 1
Alcohol ≥3 units per day 1
COPD and postbronchodilator FEV1 < 50% predicted 1
*Diseases or medications associated with increased fracture risk: untreated
hypogonadism, inflammatory bowel diseases or malabsorption, chronic
inflammatory diseases, organ transplantation, diabetes mellitus, untreated
hyperthyroidism or over substituted hypothyroidism, primary hyperparathyroidism,
pernicious anaemia and any past or current use of oral glucocorticoids for at
least 3 months.
COPD-adapted risk score ≥4 represents increased fracture risk.diagnosed vertebral fracture or important clinical risk
factors, are candidates for fracture prevention.
Since vertebral fractures are related with increased
fracture risk independently of BMD [39], imaging of
the thoracic and lumbar spine is advocated for fracture
risk evaluation and can be performed by conventional
radiography or DXA-based lateral images of the spine
(vertebral fracture assessment [VFA]). If lateral X-rays of
the thorax are available for evaluating lung involvement,
pulmonologists are in a privileged position to evaluate
these images for the presence of vertebral fractures, as
they are often overlooked or not reported by radiologists
[40]. Vertebral fractures are classified according to
Genant’s visual semi-quantitative method into wedge,
biconcave or crush and into grade 1 (20 to 25% reduc-
tion in height and 10 to 20% reduction of the pro-
jected vertebral area), grade 2 (25 to 40% reduction in
height and 20 to 40% reduction of the projected verte-
bral area) and grade 3 (more than 40% reduction in
height and area) [41].
The fracture risk assessment tool (FRAX) (https://
www.shef.ac.uk/FRAX/tool.aspx) might be additionally
helpful to select patients who benefit from fracture pre-
vention therapy. However, the FRAX tool has some dis-
advantages. COPD, physical inactivity and increased risk
of falls have been related with osteoporosis and frac-
tures, but are not included in the FRAX model. In
addition, longitudinal studies with COPD patients using
the FRAX tool for fracture prediction are not yet
available.
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tients are at high risk of fracture and are advocated to
consider fracture prevention:
1. A prevalent non-traumatic vertebral fracture,
2. Osteoporosis in the spine or hip,
3. Osteopenia with additional risk factors, such as a
newly diagnosed vertebral fracture or important
clinical risk factors (e.g. increased fall risk or high
FRAX score).
Step 3: Differential diagnosis
In COPD patients, the following causes of secondary
osteoporosis and other metabolic bone diseases are fre-
quently documented: vitamin D deficiency (58%) [42],
secondary hyperparathyroidism (10%) [43], renal insuffi-
ciency (22%) [6] and hypogonadism (22-69%) [44].
Therefore, screening for the presence of secondary
osteoporosis or other metabolic bone diseases is advo-
cated. Screening should exist of medical history, physical
examination and biochemistry tests, including serum
calcium, phosphate, creatinine, albumin, erythrocyte
sedimentation rate, 25-hydroxyvitamin D, 24 h urine cal-
cium in men, and serum testosterone in men younger
than 70 years [45]. Additional tests may be needed based
on clinical and biochemistry findings in order to detect
hyperparathyroidism, multiple myeloma, hypercortiso-
lism, celiac disease, or other causes of secondary osteo-
porosis and metabolic bone diseases. These results
should be taken into account and treated when possible
before starting fracture prevention.
Step 4: Therapy
Fracture prevention starts with advising a healthy life-
style, including quit smoking, physical exercise (walking
during 30 minutes 3 times a week), limiting alcohol in-
take and healthy diet with both sufficient calcium (total
intake of 1000 to 1200 mg per day) and vitamin D
[46,47]. If dietary calcium intake is insufficient (less than
1000 mg per day), calcium supplementation is recom-
mended. As an example: a patient who does not use any
dairy products needs 1000 mg calcium supplementation
per day; a patient who uses 1 to 2 dairy products per day
needs 500 mg calcium supplementation per day; and a
patient who uses 3 or more dairy products per day does
not need any calcium supplementation. Calcium supple-
mentation does not need to be higher, as a too high
calcium intake could be related with an increased risk
of cardiovascular events [48,49]. To optimise calcium
homeostasis, sufficient vitamin D is necessary. A dose of
800 IU vitamin D per day is advocated [16,50]. In COPD
patients with a history of >1 falls in the last year, fall
prevention is advocated [51]. Exacerbations of COPD
might contribute to bone loss via increased systemicinflammation, use of corticosteroids and reduced phys-
ical activity. Therefore, (chest) physicians should con-
sider carefully the prescription of oral glucocorticoids in
each individual patient and they should support patients
to keep moving. More research is however necessary to
investigate the impact of these isolated components re-
lated with exacerbations on bone metabolism.
Drug treatment includes two categories of drugs:
antiresorptive medications such as bisphosphonates or
denosumab and osteo-anabolics such as the 1–34
rhPTH fragment teriparatide. In the Dutch guideline
[16], alendronate and risedronate are recommended as
first choice medications because of their broad-spectrum
fracture prevention and generic availability. Denosumab
and zoledronate are indicated in case of intolerance for
oral bisphosphonates. Teriparatide is indicated in severe
osteoporosis, i.e. patients who develop new fractures in
spite of adequate treatment with antiresorptive drugs.
Notably, the clinical effects of these medications have
not been studied in randomised controlled trials with
COPD patients.
Prevention of glucocorticoid induced osteoporosis
Prevention of glucocorticoid induced osteoporosis de-
pends on the background risk and the dose and duration
of glucocorticoid treatment [16]. Bisphosphonates are
advocated in: 1, patients who use more than 15 mg
prednisone equivalents per day; 2, patients who had a
fracture after the age of 50 years and use, or are going to
use, oral glucocorticoids for 3 or more months; and 3,
postmenopausal women and men older than 70 years
who use 7.5 to 15 mg prednisone equivalents per day. In
premenopausal women and men younger than 70 years
who use 7.5 to 15 mg prednisone equivalents per day
and in patients who use less than 7.5 mg prednisone
equivalents per day, a low BMD is an indication for
treatment, although no consensus exists about the
level of T-score for treatment decision (T-score < −1.0
or < −1.5).
Step 5: Follow-up
The aim of follow-up is to check adherence and toler-
ance and to decide about efficacy and duration of ther-
apy. As adherence to fracture prevention medication is
low, regular follow-up is advocated, e.g. 3 months after
start of treatment, and then yearly. In case of intolerance
for oral bisphosphonates, treatment can be switched to
IV zoledronate or SC denosumab. In case of a new frac-
ture after one year of adequate antiresorptive drug ther-
apy, teriparatide is advocated during 2 years (Figure 3).
After 5 years of treatment with bisphosphonates, re-
evaluation of clinical risk factors, BMD and imaging of
the spine should take place (Figure 4). If fracture risk is
low, treatment can be interrupted, with re-evaluation
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tive treatment can be continued, with re-evaluation after
5 years. After treatment of teriparatide, antiresorptive
drugs are advocated to conserve the gain in bone density
and structure.
Limitations and future research directions
In COPD patients, there are no guidelines available on
the necessity or frequency of serial DXA scanning and
vertebral fracture assessments. Graat-Verboom and col-
legues [52] studied the incidence of osteoporosis during
3 years follow-up. The prevalence of osteoporosis in-
creased from 47% to 61% in 3 years. The increase in
osteoporosis was mostly due to newly diagnosed verte-
bral fractures. In addition, osteopenia at the hip seemed
to be a predictor of osteoporosis. Based on their data,
Graat-Verboom and colleagues [52] advised to perform
vertebral fracture assessments in all COPD patients
every year and to perform DXA scanning in patients
with osteopenia at the hip every 3 years. Since this is the
only longitudinal evaluation of osteoporosis in COPD
patients, additional research is necessary to provide
guidelines on the necessity and frequency of serial DXA
scanning and vertebral fracture assessments.
Although the 5-step clinical approach for fracture pre-
vention has been based on the current literature on
osteoporosis in COPD, it has not been validated yet.
Therefore, future research should be focussed on algo-
rithms to identify COPD patients at high risk of fracture
and beneficial effects of anti-fracture therapy in COPD
patients.
Conclusions
Although osteoporosis and its related fractures are com-
mon in patients with COPD, patients with increased
fracture risk are poorly identified and undertreated.
Here, we described a clinical systematic approach for
fracture prevention in COPD patients starting with clin-
ical case finding, followed by risk evaluation, differential
diagnosis, treatment and follow-up.
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